Empowering the body to fight disease
The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for acute treatment of patients with cardiovascular diseases, where vascular damage and inflammation are involved.
Annexin’s drug candidate ANXV is a recombinant human Annexin A5. It is in development for intravenous administration in patients with acute vascular diseases, where ANXV is expected to improve the body’s own ability to protect and repair blood vessels.
Welcome to the Annexin Pharmaceuticals AB website. In order to optimize your use of our website, we use cookies. A cookie is a text file that is stored on your computer. If you would like further information on what a cookie is, what cookies we use, what cookies are for or how to block or delete cookies, please read “About Cookies“. By continuing, you agree to our use of cookies.